A bicentre open label randomised pilot study for proof of safety and efficacy of immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1-FV versus a depot extract of natural birch allergen.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2013
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Hypersensitivity
- Focus Therapeutic Use
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2006 New trial record.